Across TCGA pan-cancer cohorts, CXorf21 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CXorf21 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CXorf21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXorf21 expression acts as an unfavorable survival marker.
UCEC are the cancer types where CXorf21 Mutation most reproducibly stratifies survival.